Thursday, 07 July 2022

IPA to organise 7th Global Pharma Quality Summit from Feb 24-25, 2022

22 February 2022 | News

The summit will feature over 30 global leaders and regulators taking part in 15 sessions covering key aspects of manufacturing and quality with a view on sustainability

Image credit: Shutterstock

Image credit: Shutterstock

The Indian Pharmaceutical Alliance (IPA) will host the seventh edition of the 'Global Pharmaceutical Quality Summit (GPQS).' The theme for this year is 'Making quality pharmaceuticals in India, sustainably, for the World' and is scheduled from February 24 to 25, 2022. The forum aims to bring manufacturers and regulators on a common platform to facilitate discussions resulting in meaningful and actionable outcomes in quality. The summit will feature over 30 global leaders and regulators taking part in 15 sessions covering key aspects of manufacturing and quality with a view on sustainability.

The conference will commence with a keynote address by S Aparna, Secretary, Department of Pharmaceuticals, and a special address by Dr V G Somani, Drugs Controller General of India. The two-day summit will include technical sessions, panel discussions and special addresses by global subject matter experts on topics such as quality excellence in pharmaceuticals operations, vaccine development, and learnings on quality excellence from other industries, among others.

The concluding session will have a CEO panel discussion from leading Indian Pharma companies such as Cadila, Cipla, Dr Reddy’s, Lupin, Sun Pharma, and Torrent Pharma to deliberate on ‘Sustainable end-to-end operations & Quality Excellence.’

The key regulators joining the Summit are Dr V G Somani, DCG(I), Dr Rogério Gaspar, Director, Regulation and Prequalification Department, WHO, Dr Manisha Shridhar, Regional Advisor, WHO – SEARO, Dr Douglas Throckmorton, Deputy Director for Regulatory Platforms, USFDA, Kristan Callahan, International Relations Specialist, USFDA India Office and Dr Sotirios Paraschos, Inspector, Certification of Substances Department, EDQM
 
The forum is expected to witness participation from 1000+ registered participants, and invitees from CDSCO, media, senior leadership WHO India Office, USFDA India Office, IGBA, PDA, USP, OPPI, IDMA, Academia and IPA Executive Council. The knowledge partner for the summit is McKinsey & Company and collaborators are Invest India, USP and PDA.


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account